To access the live webcast of BridgeBio's presentation, please visit the"Events" page within the Investors section of the BridgeBio website at or register online using the following link,. A replay of the conference call and webcast will be archived on the Company's website and will be available for at least 30 days following the event. About AttrubyTM (acoramidis) INDICATION Attruby is a transthyretin stabilizer indicated for the treatment of the cardiomyopathy of wild-type or variant transthyretin-mediated amyloidosis (ATTR-CM) in adults to reduce cardiovascular death and cardiovascular-related hospitalization. IMPORTANT SAFETY INFORMATION Adverse Reactions Diarrhea (11.6% vs 7.6%) and upper abdominal pain (5.5% vs 1.4%) were reported in patients treated with Attruby versus placebo, respectively. The majority of these adverse reactions were mild and resolved without drug discontinuation.